Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 384 participants.
Also called NCT04026165
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 384 participants
- Sponsor
- Registry
-
NCT04026165 -
2018-003951-39
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Japan, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT04026165. Randomized; double masking; primary purpose treatment. Start 2019-07-24 (actual); primary completion 2021-09-03 (actual). Results posted on 2022-12-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
- Acronym
- MOSAIC
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- SEL
- Intervention (Drug)
- Placebo
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct04026165- Content hash
e6765804b084dfa079177a006dafe28035f9f8f9323311e33a568e65645d4c4b